Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion

Abstract

Objectives: Experimental evidences indicate that leptin is involved in the neuroinflammatory process sustaining multiple sclerosis (MS). However, the relationship between leptin and body fat, as assessed by body mass index (BMI), in MS was not previously evaluated. It was the aim of this study to compare serum leptin levels between patients with MS and healthy controls and to evaluate the possible relationship between circulating leptin levels and disease severity. Patients and Methods: Eighty-four MS patients and 57 sex-matched healthy volunteers were enrolled. Serum leptin levels were measured in all patients and controls. MS patients were stratified in 3 groups according to their degree of disability as assessed by the Expanded Disability Status Scale (EDSS). Patients were classified as having low (33 patients with an EDSS score <1.5), intermediate (28 patients with an EDSS score from 2 to 3) and high disability (23 patients with an EDSS score ≥3.5). Results: No significant differences in serum leptin levels and BMI were observed between patients and controls. In patients with MS, serum leptin levels were significantly correlated with BMI in those patients with low (R² = 0.363; p < 0.001) and intermediate disability (R² = 0.408; p < 0.001), but not in patients with a higher disability score (R² = 0.064; p = 0.256). Conclusion: BMI, the major determinant of leptin level in physiological conditions, has a minor role in determining the serum levels of leptin in MS patients with a high EDSS score. Future longitudinal studies will be required in order to provide further insights into the regulation of leptin secretion in patients with MS.

The role of cannabinoids and leptin in neurological diseases

“…Therefore, it has been hypothesized that leptin is effective in reducing inflammation and autoimmunity seen in immune‐mediated neurological diseases, including MS . Several experimental and clinical studies support this hypothesis, reporting that the level of serum leptin was higher in patients with MS in remission compared to healthy subjects and that the level of serum leptin significantly decreased after 2 months of interferon beta treatment . These studies concluded that the increase in the level of serum leptin activates immune cells, resulting in the release of cytokines, which, in turn, further increase leptin production and finally reverse the inflammatory process in MS .…”

The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis

“…MS usually commences in early adulthood, with paralysis, sensory disturbances, lack of coordination and visual impairment among its most frequent features [3]. The disease often begins with an ‘attack' or ‘flare' that lasts from a few days to weeks and is followed by remission that most often lasts from a few months to years [4,5]. The variable course of the disease may be reflected in the differences seen at the morphological level by magnetic resonance imaging and histopathologic evaluations of the CNS, which also vary significantly [6].…”

Emerging role of leptin in rheumatoid arthritis

“…Normal leptin levels crucially maintain and regulate the body's immune function. Emerging evidence indicates that leptin acts as a proinflammatory cytokine in immune responses such as systemic lupus erythematosus (SLE) [3][4][5][6], RA [7][8][9][10], multiple sclerosis (MS) [11][12][13] and psoriasis [14][15][16]. Leptin could be a member of the cytokine network managing the inflammatory immune response and host defence mechanisms.…”